Site is Being Upgraded

Lifespan extension therapy:  Telmisartan [Brand name: Micardis], an anit-hypertensive medication, increases life span via up-regulation of its target gene BubR1, 9/January/2017, 11.47 pm

Vitamin-based Combinatorial therapy for reversing TIIDM: A pharmaceutical mixture encompassing Pyridoxamine and Vitamin K1 (PMVK1)augments the expression of FGF19 and FGF1,   attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIIDM via up regulation of its target gene, 9/January/2017, 11.39 pm
January 9, 2018
Life-extension therapy: Tomatidine, isolated from unripe tomoto, inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span, 9/January/2017, 11.59 pm
January 9, 2018
Show all

 What they say: Introduction: 

A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July  2014 issue of the journal  “EMBO”, by Prof Sinclair, North BJ, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Lifespan extension therapy:  Telmisartan [Brand name: Micardis], an anit-hypertensive medication, increases life span via up-regulation of its target gene BubR1


What is known? 

Telmisartan has been shown to shown to lower blood pressure. However, the exact mechanism of action is far from clear.


From research findings to therapeutic Opportunity: 

This study suggests, for the first time, that Telmisartanby increasing the expression of its target gene, it may: (a) increase the expression of BuBR1; (b) decrease the expression of p70 S6 Kinase; and (c) regulate the expression of a number of longevity-promoting molecules (Fig. 1).

[easy_payment currency=”USD”]

Figure 1. Telmisartan may extend  mammalian life span via up regulation of BuBR1 and down regulation of p70 S6 Kinase

Figure 2. The chemical structure of Telmisartan. Tomatidine may function as a longevity-promoting agent through up regulation of BuBR1.

 

Thereby, it may: (1) increase insulin sensitivity; (2) attenuate cognitive impairment; (3) delay diseases of aging; (4) slow down cardiac aging; (5) promote resistance to bone, immune and motor dysfunction; (6) promote tissue rejuvenation; and (7) prolong median life span. Thus, pharmacological formulations encompassing “Telmisartan or its analogues, either alone or in combination with other drugsat lower doses may be used to extend the lifespan of an individual (fig. 1).


Details on the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $500#

Undisclosed mechanistic information: How Telmisartan  increases the expression of BubR1 and extends mammalian life-span

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

# Research cooperation


References

Web: http://genomediscovery.org or http://newbioideas.com

CitationBoominathan, L., Lifespan extension therapy:  Telmisartan [Brand name: Micardis], an anit-hypertensive medication, increases life span via up-regulation of its target gene BubR1, 9/January/2017, 11.50 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.